CN113557060A - 用于晚期实体瘤癌症的治疗性rna - Google Patents

用于晚期实体瘤癌症的治疗性rna Download PDF

Info

Publication number
CN113557060A
CN113557060A CN202080010320.9A CN202080010320A CN113557060A CN 113557060 A CN113557060 A CN 113557060A CN 202080010320 A CN202080010320 A CN 202080010320A CN 113557060 A CN113557060 A CN 113557060A
Authority
CN
China
Prior art keywords
cancer
rna
tumor
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010320.9A
Other languages
English (en)
Chinese (zh)
Inventor
S·马斯恰里
S·约克
K·许
N·阿夸维拉
M·贝尔纳多
R·贾布洛斯基
U·萨欣
F·吉塞克
Z·吉拉科娃·特恩科娃
T·R·瓦格纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN113557060A publication Critical patent/CN113557060A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080010320.9A 2019-01-21 2020-01-17 用于晚期实体瘤癌症的治疗性rna Pending CN113557060A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962794889P 2019-01-21 2019-01-21
US62/794,889 2019-01-21
US201962926384P 2019-10-25 2019-10-25
US62/926,384 2019-10-25
EP19306461.5 2019-11-12
EP19306461 2019-11-12
PCT/US2020/014019 WO2020154187A1 (en) 2019-01-21 2020-01-17 Therapeutic rna for advanced stage solid tumor cancers

Publications (1)

Publication Number Publication Date
CN113557060A true CN113557060A (zh) 2021-10-26

Family

ID=69582158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010320.9A Pending CN113557060A (zh) 2019-01-21 2020-01-17 用于晚期实体瘤癌症的治疗性rna

Country Status (13)

Country Link
US (1) US20220040218A1 (https=)
EP (1) EP3914354A1 (https=)
JP (1) JP2022518235A (https=)
KR (1) KR20210119451A (https=)
CN (1) CN113557060A (https=)
AU (1) AU2020211584A1 (https=)
BR (1) BR112021013887A2 (https=)
CA (1) CA3125773A1 (https=)
IL (1) IL284646A (https=)
MX (1) MX2021008604A (https=)
SG (1) SG11202107395VA (https=)
TW (1) TW202043273A (https=)
WO (1) WO2020154187A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507963A (zh) * 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428301A (zh) 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035565A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
WO2018160540A1 (en) * 2017-02-28 2018-09-07 Sanofi Therapeutic rna
CN109153723A (zh) * 2016-05-13 2019-01-04 瑞泽恩制药公司 抗pd-1抗体与放射的组合治疗癌症
CN110536905A (zh) * 2017-02-21 2019-12-03 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
WO2020041655A1 (en) * 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
CN113507963A (zh) * 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
WO2023086459A2 (en) * 2021-11-12 2023-05-19 The Brigham And Women's Hospital, Inc. Gene editing and engineering stem cells for drug delivery
CN116568317A (zh) * 2020-06-22 2023-08-08 免疫实验室私人有限公司 用于癌症治疗的重组多肽和组合
CN117043193A (zh) * 2021-02-11 2023-11-10 瑞泽恩制药公司 通过施用新辅助pd-1抑制剂治疗癌症的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035565A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
CN109153723A (zh) * 2016-05-13 2019-01-04 瑞泽恩制药公司 抗pd-1抗体与放射的组合治疗癌症
CN109153724A (zh) * 2016-05-13 2019-01-04 瑞泽恩制药公司 通过施用pd-1抑制剂治疗皮肤癌的方法
CN110536905A (zh) * 2017-02-21 2019-12-03 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
TW201842921A (zh) * 2017-02-28 2018-12-16 法商賽諾菲公司 治療性ｒｎａ
CN110337305A (zh) * 2017-02-28 2019-10-15 赛诺菲 治疗性rna
WO2018160540A1 (en) * 2017-02-28 2018-09-07 Sanofi Therapeutic rna
WO2020041655A1 (en) * 2018-08-24 2020-02-27 Sanofi Therapeutic rna for solid tumor cancers
CN113507963A (zh) * 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
US20220288199A1 (en) * 2019-01-21 2022-09-15 Sanofi Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers
CN116568317A (zh) * 2020-06-22 2023-08-08 免疫实验室私人有限公司 用于癌症治疗的重组多肽和组合
CN117043193A (zh) * 2021-02-11 2023-11-10 瑞泽恩制药公司 通过施用新辅助pd-1抑制剂治疗癌症的方法
WO2023086459A2 (en) * 2021-11-12 2023-05-19 The Brigham And Women's Hospital, Inc. Gene editing and engineering stem cells for drug delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOSHE SADE-FELDMAN等: "Resistance to checkpoint blockade therapy through inactivation of antigen presentation", NATURE COMMUNICATIONS, vol. 8, no. 1, pages 2, XP055514594, DOI: 10.1038/s41467-017-01062-w *
PADMANEE SHARMA等: "Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy", CELL, vol. 168, no. 4, pages 707, XP029935389, DOI: 10.1016/j.cell.2017.01.017 *
全晓红;: "细胞因子疗法抗肿瘤研究进展", 赤峰学院学报(自然科学版), no. 04, pages 32 - 35 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113507963A (zh) * 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体

Also Published As

Publication number Publication date
SG11202107395VA (en) 2021-08-30
EP3914354A1 (en) 2021-12-01
US20220040218A1 (en) 2022-02-10
JP2022518235A (ja) 2022-03-14
TW202043273A (zh) 2020-12-01
KR20210119451A (ko) 2021-10-05
AU2020211584A1 (en) 2021-08-26
BR112021013887A2 (pt) 2021-09-21
WO2020154187A1 (en) 2020-07-30
IL284646A (en) 2021-08-31
CA3125773A1 (en) 2020-07-30
MX2021008604A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
Wang et al. Advancing to the era of cancer immunotherapy
Sun et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Schoenfeld et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors
CN113507963A (zh) 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体
Gray et al. Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non–small cell lung cancer
EP3508502B1 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
AU2007213920B2 (en) Treatment of metastatic breast cancer
AU2016291161A1 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using SLNCR isoforms
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
Pham et al. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
JP2022505647A (ja) 腫瘍の処置方法
WO2022174234A2 (en) Biomarkers for cancer treatment
CN113557060A (zh) 用于晚期实体瘤癌症的治疗性rna
Lakhani et al. A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
El-Khoueiry et al. First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors
Bedard et al. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
Siu et al. AZD8701, an antisense oligonucleotide targeting FOXP3 mRNA, as monotherapy and in combination with durvalumab: a phase I trial in patients with advanced solid tumors
van der Westhuizen et al. Repurposing azacitidine and carboplatin to prime immune checkpoint blockade–resistant melanoma for anti-PD-L1 rechallenge
Beyaert et al. Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
Vergato et al. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer
JP2023515190A (ja) Ａｐｃ欠損がんの治療のための方法および組成物
Ma et al. SLC5A11 Mediates Metformin-Induced PD-L1 Suppression to Enhance Cancer Immunotherapy through AMPK–IRF1 Signaling
JP2022550110A (ja) 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのｆｇｆｒ遺伝子改変癌におけるｆｇｆｒ阻害剤の使用
WO2021225963A2 (en) Methods and compositions for induction of antitumor immunity
Rosato et al. Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211026